GoAI
Get started
Precision BioSciences, Inc. logo

Precision BioSciences, Inc.

DTIL

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$8.85

+$0.13 · +1.49%

Aug 21, 4:00 PM ET

DTIL company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

47

Fair Value

Momentum

79

Gaining

Sentiment

68

Bullish

Risk resilience

50

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Biotechnology
Sector
Healthcare
Headquarters
US

Market position

Day range

Current $8.85

52-week range

Current $8.85

Open
$8.92
Previous close
$8.72
Volume
305.18K
Market cap
113.53M USD
50-day average
$7.5874
+16.64% above average
200-day average
$6.0632
+45.96% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-3.17×
P/B (TTM)
5.05×
P/S (TTM)
2.52×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
100.00%
Operating margin
-80.78%
Net margin
-117.04%

Financial health

Debt / equity
0.62×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends154%-63%-281%-499%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 100.00%Operating margin, FY2021: -34.08%Operating margin, FY2022: -248.26%Operating margin, FY2023: -89.76%Operating margin, FY2024: -38.08%Operating margin, FY2025: -152.19%Net margin, FY2021: -26.49%Net margin, FY2022: -444.80%Net margin, FY2023: -125.84%Net margin, FY2024: 10.43%Net margin, FY2025: -133.45%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 100.00%. Operating margin FY2021 -34.08%. Operating margin FY2022 -248.26%. Operating margin FY2023 -89.76%. Operating margin FY2024 -38.08%. Operating margin FY2025 -152.19%. Net margin FY2021 -26.49%. Net margin FY2022 -444.80%. Net margin FY2023 -125.84%. Net margin FY2024 10.43%. Net margin FY2025 -133.45%.

Income trends

Revenue

34.26M USD-50.12%

Operating income

−52.15M USD-99.33%

Net income

−45.72M USD−52.89M USD
Income trends across reported periods138.25M USD47.38M USD−43.49M USD−134.35M USDRevenue, FY2021: 115.53M USDRevenue, FY2022: 25.1M USDRevenue, FY2023: 48.73M USDRevenue, FY2024: 68.7M USDRevenue, FY2025: 34.26M USDOperating income, FY2021: −39.38M USDOperating income, FY2022: −62.31M USDOperating income, FY2023: −43.74M USDOperating income, FY2024: −26.16M USDOperating income, FY2025: −52.15M USDNet income, FY2021: −30.6M USDNet income, FY2022: −111.64M USDNet income, FY2023: −61.32M USDNet income, FY2024: 7.17M USDNet income, FY2025: −45.72M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 115.53M USD. Revenue FY2022 25.1M USD. Revenue FY2023 48.73M USD. Revenue FY2024 68.7M USD. Revenue FY2025 34.26M USD. Operating income FY2021 −39.38M USD. Operating income FY2022 −62.31M USD. Operating income FY2023 −43.74M USD. Operating income FY2024 −26.16M USD. Operating income FY2025 −52.15M USD. Net income FY2021 −30.6M USD. Net income FY2022 −111.64M USD. Net income FY2023 −61.32M USD. Net income FY2024 7.17M USD. Net income FY2025 −45.72M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue34.26M USD68.7M USD48.73M USD25.1M USD115.53M USD
Gross profit34.26M USD68.7M USD48.73M USD25.1M USD115.53M USD
Research and development54.17M USD59.56M USD53.38M USD46.12M USD115.24M USD
Selling, general, and administrative32.24M USD35.3M USD39.09M USD41.28M USD39.67M USD
Operating expenses86.41M USD94.86M USD92.46M USD87.41M USD154.91M USD
Interest income4.24M USD6.76M USD7.69M USD3.47M USD208K USD
Interest expense1.42M USD1.78M USD2.23M USD1.11M USD132K USD
Depreciation and amortization2.75M USD4.58M USD8.26M USD9M USD10.2M USD
Operating income−52.15M USD−26.16M USD−43.74M USD−62.31M USD−39.38M USD
Net income−45.72M USD7.17M USD−61.32M USD−111.64M USD−30.6M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
27%
3 beats, 8 misses, 0 met estimates
Average EPS surprise
-236.63%
11 comparable reports
Latest EPS result
-1.26
Estimate -0.8 · Miss by 56.72%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.39-0.25-1.9-3.54Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 26, 2025: actual -3.2, estimate -2.09, surprise -53.11%, Miss. Q2 2025, reported May 15, 2025: actual -2.21, estimate -0.43, surprise -413.95%, Miss. Q3 2025, reported Aug 7, 2025: actual -2.13, estimate -0.09, surprise -2266.67%, Miss. Q4 2025, reported Nov 3, 2025: actual -1.84, estimate -0.31, surprise -493.55%, Miss. Q1 2026, reported Mar 12, 2026: actual 1.05, estimate -0.21, surprise +600.00%, Beat. Q2 2026, reported May 5, 2026: actual -0.75, estimate -0.27, surprise -177.78%, Miss. Q3 2026, reported Aug 6, 2026: actual -1.26, estimate -0.804, surprise -56.72%, Miss. Q4 2026, reported Nov 2, 2026: actual —, estimate -0.844, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates36.94M24.63M12.32M11.05KQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26EstimateQ4 '26Estimate
Q1 2025, reported Mar 26, 2025: actual 638K USD, estimate 10M USD, surprise -93.62%, Miss. Q2 2025, reported May 15, 2025: actual 29K USD, estimate 6.27M USD, surprise -99.54%, Miss. Q3 2025, reported Aug 7, 2025: actual 18K USD, estimate 5.4M USD, surprise -99.67%, Miss. Q4 2025, reported Nov 3, 2025: actual 13K USD, estimate 9.08M USD, surprise -99.86%, Miss. Q1 2026, reported Mar 12, 2026: actual 34.2M USD, estimate 9.08M USD, surprise +276.90%, Beat. Q2 2026, reported May 5, 2026: actual 10.84M USD, estimate 4.05M USD, surprise +167.60%, Beat. Q3 2026, reported Aug 6, 2026: actual —, estimate 740K USD, surprise —, Comparison unavailable. Q4 2026, reported Nov 2, 2026: actual —, estimate 1.1M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

12 ratings
Strong buy00%
Buy975%
Hold325%
Sell00%
Strong sell00%

DTIL peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding DTIL

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
5.44M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
4.82M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
2.18M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
1.91M
Weight
0.01%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
1.02M
Weight
0.02%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
943.44K
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
727.85K
Weight
0.05%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF logoGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC
Market value
304.5K
Weight
0.03%
AUM
1.08B USD
Expense ratio
0.20%
Price / 1D
$91.32+0.82%

Continue in GoAI

Research DTIL

research.disclaimer